Direct-acting oral anticoagulants use prior to COVID-19 diagnosis and associations with 30-day clinical outcomes

José Miguel Rivera‐Caravaca; Benjamin J. R. Buckley; Stephanie L. Harrison; Elnara Fazio‐Eynullayeva; Paula Underhill; Francisco Marı́n; Professor Gregory Lip

doi:10.1016/j.thromres.2021.06.014

Back

Direct-acting oral anticoagulants use prior to COVID-19 diagnosis and associations with 30-day clinical outcomes

Article 2021 en

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2021

Efficacy and safety of direct-acting oral anticoagulants compared to vitamin K antagonists in COVID-19 outpatients with cardiometabolic diseases

José Miguel Rivera‐Caravaca, Stephanie L. Harrison, Benjamin J. R. Buckley, Elnara Fazio‐Eynullayeva, Paula Underhill, Francisco Marı́n, Professor Gregory Lip

Editorial Material2023

Use of Direct-Acting Oral Anticoagulants in Patients With Atrial Fibrillation and Chronic Liver Disease

Theresa Hydes, Professor Gregory Lip, Deirdre A. Lane

Article2021

Associations between COVID-19 and 30-day thromboembolic events and mortality in people with dementia receiving antipsychotic medications

Stephanie L. Harrison, Benjamin J. R. Buckley, Deirdre A. Lane, Paula Underhill, Professor Gregory Lip

Article2020

Label Adherence of Direct Oral Anticoagulants Dosing and Clinical Outcomes in Patients With Atrial Fibrillation

Hee Tae Yu, Pil‐Sung Yang, Eunsun Jang, Tae‐Hoon Kim, Jae‐Sun Uhm, Jong‐Youn Kim, Hui‐Nam Pak, Moon‐Hyoung Lee, Professor Gregory Lip, Boyoung Joung

Article2020

End-Stage renal disease and 30-day mortality for adults with and without COVID-19

Stephanie L. Harrison, Benjamin J. R. Buckley, Elnara Fazio‐Eynullayeva, Paula Underhill, Deirdre A. Lane, Professor Gregory Lip